Premium
A reversible enteropathy complicating continuous hepatic artery infusion chemotherapy with 5‐fluoro‐2‐deoxyuridine
Author(s) -
Gluck W. Larry,
Akwari Onye E.,
Kelvin Frederick M.,
Goodwin Bonnie J.
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19851115)56:10<2424::aid-cncr2820561015>3.0.co;2-z
Subject(s) - medicine , floxuridine , enteropathy , perfusion , chemotherapy , gastroenterology , superior mesenteric artery , deoxyuridine , diarrhea , colorectal cancer , cancer , fluorouracil , dna , disease , biology , genetics
This article describes two patients with hepatic metastases from colorectal cancer in whom a reversible enteropathy developed during the administration of hepatic artery infusion chemotherapy with 5‐fluoro‐2‐deoxyuridine (5‐FUdR) via an Infusaid Series 400 pump (Infusaid Corp., Sharon, MA). Both patients had severe diarrhea and signs that suggested small bowel obstruction. Barium studies revealed a distinctive radiologic appearance of severe narrowing of the ileum associated with complete loss of normal mucosal patterns. Results of an extensive evaluation for an infectious or toxin‐related enterocolitis were negative. Perfusion studies confirmed the appropriate position of the catheters and revealed no extrahepatic perfusion. Systemic shunting of the 5‐FUdR through the liver or tumor bed is postulated as the primary event, with the small bowel manifesting the major toxicity.